Clinical Trial Supplies Market

The report "Clinical Trial Supplies Market by Service [Manufacturing, Packaging (Primary, Secondary), Logistics], Phases, Type (Small Molecules, Biologics, Vaccine), Therapeutic Areas (Oncology, Neurology, Ophthalmology, Dermatology), Region - Global Forecast to 2031" The clinical trial supplies market is projected to reach USD 8.95 billion by 2031, up from USD 5.60 billion in 2026, at a CAGR of 9.8%.

Browse 420 market data Tables and 50 Figures spread through 450 Pages and in-depth TOC on "Clinical Trial Supplies Market by Service [Manufacturing, Packaging (Primary, Secondary), Logistics], Phases, Type (Small Molecules, Biologics, Vaccine), Therapeutic Areas (Oncology, Neurology, Ophthalmology, Dermatology), Region - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/clinical-trial-supplies-market-172240059.html

The clinical trial supplies market is skyrocketing due to factors such as the adoption of digital solutions, AI, and blockchain for tracking and optimizing supply distribution; increasing demand for specialized storage and transportation solutions; and growing use of comparators in head-to-head studies. Furthermore, higher R&D spending by pharma and biotech companies and government and private funding initiatives supporting drug development are further propelling the market growth.

The Logistics & Distribution Services segment is anticipated to dominate the market during the forecast period.

The services segment is sub-segmented into logistics & distribution services, storage & retention services, packaging, labeling and blinding services, manufacturing services, comparator sourcing services and other services. The logistics & distribution services segment dominated the market. The shift toward decentralized and direct-to-patient (DTP) trials has increased the need for flexible distribution models, enabling home-based delivery with real-time monitoring. As pharmaceutical and biotechnology companies expand their pipelines, demand for comparators, ancillary supplies, and investigational drugs is rising, driving growth in specialized sourcing services.

Phase III segment dominated the clinical trial supplies market in 2025

The phase segment is divided into Phase I, Phase II, Phase III, Phase IV, and Phase BA/BE. The Phase III segment dominated the clinical trial supplies market in 2025 because it plays a critical role in the drug development process and requires large-scale patient recruitment and extensive supply chain management. The Phase II segment is expected to grow at a significant CAGR during the forecast period in the clinical trial supplies market, driven by the increasing number of drug candidates advancing from preclinical to early-stage clinical trials. The rising focus on innovative therapies, including biologics, gene therapies, and targeted drugs, has led to a surge in Phase II trials, which assess the efficacy and optimal dosing of investigational treatments.

Oncology segment dominated the therapeutic area segment in 2025

The therapeutic area segment is further divided into oncology, neurology, respiratory disorders, metabolic disorders/endocrinology, cardiovascular system disorders, dermatology, gastrointestinal disorders, immunological disorders, infectious diseases, psychiatry, ophthalmology, hematology, genitourinary and women's health, and others. The oncology segment dominated in 2025 due to factors such as an increased number of clinical trials in oncology. Oncology trials require specialized drug formulations, complex dosing regimens, and stringent regulatory compliance, increasing the need for efficient supply chain management, cold chain logistics, and sourcing of comparator drugs.

Pharmaceutical & Biotechnology Companies segment led the end-user market in 2025.

By end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and other end users. Pharmaceutical & biotechnology companies dominated the market in 2025 and are expected to grow at the highest CAGR during the forecast period of 2026-2031. The segment's dominance is attributable to the rise of biologics, cell & gene therapies, and personalized medicine, which has further fueled the need for specialized logistics, cold chain storage, and regulatory-compliant distribution. The CROs and CDMOs segment is anticipated to grow at a significant CAGR in the clinical trial supplies market due to the increasing trend of outsourcing clinical trial operations by pharmaceutical and biotechnology companies.

Asia Pacific is anticipated to grow at a significant CAGR during the forecast period.

The clinical trial supplies market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2025, North America dominated the clinical trial supplies market due to its strong pharmaceutical and biotechnology industry, high R&D investments, and well-established clinical trial infrastructure. The United States leads the region with the highest number of clinical trials, driven by major pharmaceutical companies, CROs, and CDMOs, as well as a favorable regulatory framework established by the FDA.

The prominent players operating in the clinical trial supplies market are Thermo Fisher Scientific Inc. (US), Novo Holdings A/S (Denmark), Eurofins Scientific (Luxembourg), Piramal Pharma (India), Almac Group (UK), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), among others.

Don’t miss out on business opportunities in Clinical Trial Supplies Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]